Boundless Bio (BOLD) vs Citius Oncology (CTOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Boundless Bio (BOLD) has outperformed Citius Oncology (CTOR) over the past year, gaining 105.3% versus a loss of 55.4%. Boundless Bio is the larger company by market cap ($54.8 million vs $53.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | CTOR |
|---|---|---|
| Share price | $2.32 | $0.5035 |
| Market cap | $54.78M | $53.25M |
| 1-day change | -2.52% | -10.95% |
| YTD return | +93.33% | -49.65% |
| 1-year return | +105.31% | -55.44% |
| EPS (TTM) | $-2.46 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-58.20M | $-24.76M |
| 52-week high | $3.16 | $1.83 |
| 52-week low | $0.961 | $0.491 |
| Distance from 52-week high | -26.68% | -72.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +72.41% | +694.44% |
| Average volume | 131.34K | 114.02K |
| Shares outstanding | 23.61M | 105.76M |
| Employees | 28 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed CTOR by 160.8 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
BOLD vs CTOR FAQ
Which is bigger, Boundless Bio or Citius Oncology?
Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $53.25M for Citius Oncology (CTOR).
Which stock has performed better over the past year, BOLD or CTOR?
BOLD returned +105.31% over the past 12 months, compared with -55.44% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Citius Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.